VentriPoint Diagnostics Ltd.

TSX VENTURE : VPT
OTCQX : VPTDF


VentriPoint Diagnostics Ltd.

November 12, 2012 07:00 ET

VentriPoint Expands European Network of Expert Users to Include Major Cardiac Centres in Austria, Netherlands and Germany

VentriPoint Announces European Institutional Investors Tour

SEATTLE, WASHINGTON--(Marketwire - Nov. 12, 2012) - VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF) is excited to announce the installation of its VMS™ heart analysis system in Krankenhaus der Elisabethinen Hospital in Linz, Austria, University Medical Center Utrecht, The Netherlands and the German Heart Institute Berlin, Germany.

Dr. Hans Joachim Nesser, Chief of Cardiology at Linz, and his colleagues will be studying patients with all forms of pulmonary hypertension and other heart conditions. Dr. Folkert Meijboom of the University Medical Centre Utrecht will be studying congenital heart disease patients and Dr. B. Schmitt, at the CHD department in Berlin will be studying patients with systemic right ventricles, patients after pulmonary valve replacement and patients with ventricular-assist devices (VADs).

"The knowledge of cardiovascular diseases has undergone, in recent decades, an incredible advancement, especially in the imaging sector. We are pleased to start using the VMS™ at our facility in Linz," stated Prof. Dr. Nesser, "Thanks to the leadership of Elisabethinen, we have in recent years, provided a number of pioneering works for the first time in Austria and so our department has established itself as one of the leaders in the country."

"3D imaging has added not only another dimension to imaging, but also in the understanding of right ventricular function in different states of diseases that affect the right ventricle. Theoretical considerations on the relationship between ventricular shape and ventricular function can now be visualized with the VMS™ system, measured and studied, and with that, (hopefully) better understood," stated Dr. Folkert Meijboom.

"We are continuing to build our European network of expert users by adding Linz, Utrecht and Berlin to the existing 7 centres in Europe who are clinically using the VMS™ heart analysis system." said Amol Karnick, Vice President, Sales and Business Development of Ventripoint. "Germany is an important market for us and we are pleased to have our first machine in Germany at the world-renown German Heart Institute Berlin."

In other news, Dr. George Adams, President and CEO of VentriPoint, will be touring financial centres in Europe from November 12th to the 20th, 2012, and meeting European institutional investors with Continental Advisors SA to present the Company as an investment opportunity.

About Krankenhaus der Elisabetinen Hospital, Linz, Austria

The Department of Cardiology, Angiography, and Internal Intensive Medicine at the Elisabethenin Hospital cares for patients with all forms of heart and vascular diseases with special focus on poor circulation to the heart, heart valves and heart muscle disease, and patients with heart failure and arrhythmias. In addition, the Department maintains a high academic standard by continuous participation in numerous national and international studies, as well as ongoing cooperation with American centers such as the University of Chicago and Tufts University in Boston. Numerous publications in international journals, events of national and international conferences and symposiums, as well as regular lectures and department chairs of doctors with special training courses at home and abroad, complete the picture of this high performance Department.

About University Medical Center Utrecht

The University Medical Center Utrecht is one of the largest public healthcare institutions in the Netherlands It is one of the 4 centres in the Netherlands for treatment of congenital heart disease - children and adults. Annually 300 - 400 operations for congenital heart disease are performed, with excellent scores in the European registry for surgery in congenital heart disease, the EACTS. Both in terms of (low) mortality and in complexity, the UMCU/WKZ belongs to the top European centres. It is also one of the 3 centres in the Netherlands for cardiac transplantation, with special expertise in ventricular assist devices. Main directions of research of the cardiovascular research group are "stem cell therapy" and "the failing circulation". In this category falls the research focus of Dr. Meijboom: 3D imaging and right ventricular function, in congenital heart disease and other populations, like arythmogenic RV dysplasia, of which the UMCU has the largest population in the world, and in pulmonary hypertension. With an annual budget of ~EUR1B, the hospital performs over 23,000 operations and has over 300,000 outpatient visits a year.

About German Heart Institute Berlin

The German Heart Institute Berlin (DHZB) is an internationally renowned high-performance hospital for the treatment of cardiovascular and thoracic diseases, for the implantation of mechanical circulatory support systems and for heart and lung transplantation. Each year more than 6,500 individuals are treated as inpatients, and 14,000 outpatients come to the DHZB for treatment. The DHZB performs about 2,000 diagnostic exams, and more than 1,800 invasive procedures (heart catheterization) are carried out in patients with congenital and acquired heart disease. The hospital performs more than 2,500 operations using the heart-lung machine and over 2,000 other operations on the heart. Among these, around 100 operations are heart and/or lung transplantation and 500 are heart operations in prematurely born babies, newborns, infants and children.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children and adults, and pulmonary arterial hypertension are the first applications in a suite of applications for all major heart diseases, including cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of the Company's VMS™ diagnostic tool, and the Company is pursuing the US-FDA marketing clearance through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information